Jeffrey Tate insider trades: Cyclo Therapeutics (CYTH) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jeffrey reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 20, 2023 | CYTH | ↑ Buy | 29,941 | $0.71 | $21K | Direct | Apr 24, 2023 (4d) |
| May 16, 2022 | CYTH | ↑ Buy | 3,000 | $2.12 | $6K | Direct | May 16, 2022 (0d) |
| Apr 29, 2022 | CYTH | ↑ Buy | 2,000 | $2.64 | $5K | Direct | Apr 29, 2022 (0d) |
| Mar 29, 2021 | CYTH | ↑ Buy | 2,000 | $7.50 | $15K | Direct | Mar 30, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jeffrey Tate's insider trades
Jeffrey Tate is Chief Operating Officer at Cyclo Therapeutics (CYTH). Since Mar 29, 2021, Jeffrey has reported 4 open-market purchases worth $48K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (14 filings), other transactions (6 filings), option exercises (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CYTH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.